The Patent Finder

Faron Pharmaceuticals Oy

13 patents currently held · Updated Nov 15, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
4
Ending by 2030
Dec 2026
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jul 7, 2027
    The maintenance fee for Cell and therapeutical and diagnostical methods based thereon (US 10,526,607) comes due Jul 7, 2027. Unpaid by Jan 7, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 7,727,521Method of ameliorating multi-organ failure resulting from ischemic reperfusion injury
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,975,081Biomarker for Monitoring Development of Diseases and Assessing the Efficacy of Therapies
In force
 · Medium confidence
In forceMedium confidence
US 10,526,607Cell and therapeutical and diagnostical methods based thereon
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,722,045Cell and therapeutical and diagnostical methods based thereon
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,247,730Method for determining acute respiratory distress syndrome (ARDS) related biomarkers, a method to monitor the development and treatment of ARDS in a patient
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,293,030Lyophilised Pharmaceutical Formulation and Its Use
In force
 · High confidence
In forceHigh confidence
US 10,884,000Method of Monitoring the Efficacy of the ANTI-CLEVER-1 Therapy in Cancer
In force
 · High confidence
In forceHigh confidence
US 11,046,761Humanized Anti CLEVER-1 Antibodies and Their Use
In force
 · High confidence
In forceHigh confidence
US 11,421,279Method for Determining Patient's Responsiveness to Type 1 Interferon Treatment and Use of Type 1 Interferon to Treat Patient Having Specified Single Nucleoide Polymophism
In force
 · High confidence
In forceHigh confidence
US 12,472,235Treatment of Diseases with Sequential Administration of an Agent Capable of Up-Regulating CD73 and Glucocorticoids
In force
 · High confidence
In forceHigh confidence
10 of 13 patents shown.
Pro members see all 13.
Pro members: see all 13 patents
Also on record, not counted in the 13: 1 lapsed for an unpaid fee · 3 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

3 pending · 9 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited